Isomorphic Labs was spun out of Google DeepMind, after the tech giant achieved one of the biggest biological breakthroughs in ...

Isomorphic Labs, an Alphabet-backed AI biotech firm, raised $600M to boost its AI drug design engine, expand clinical ...

The company, which uses artificial intelligence to develop new treatments, now counts the venture capital firm Thrive Capital ...

Isomorphic Labs raised $600 million in its first external funding round, led by Thrive Capital with participation from GV and ...

AlphaFold 3, the improved version of the model used by Isomorphic Labs’ drug design engine, debuted last May. It can predict ...

Isomorphic Labs, the AI drug-discovery platform that was spun out of Google's DeepMind in 2021, has raised external capital for the first time. The $600 ...

The London-based business – which launched in 2021 – will use the funds to further its research, expand its team and continue ...

AI drug discovery firm Isomorphic Labs has completed the company’s first external funding round since its 2021 founding ...

The drug discovery company, which has partnerships with Eli Lilly and Novartis, is developing AI models to design drugs and ...

Isomorphic Labs says it is advancing drug design programs across multiple therapeutic areas and drug modalities. These ...

Isomorphic Labs’ financing led the way for first quarter 2025 financings, but it comes amid headwinds for the biotech sector. Biotech financing activity has been slowing down, analysts say.

Drug design and development company Isomorphic Labs announced it raised $600 million in its first external funding round. Thrive Capital led the round, with participation from GV (Google Ventures) and ...